Vasudev Bailey

Vasudev Bailey, PhD, is a GP/ Senior Partner at ARTIS Ventures where he focuses on TechBio, investing in novel and breakthrough health and life sciences companies, including Cartography, Freenome, Lemonaid (acquired by 23andMe), Viacyte (acquired by Vertex), and Tessera. He sits on the boards of Delix Therapeutics, Eko, Excision BioTherapeutics, Outpace, Johns Hopkins Biomedical Engineering, and The Trevor Project, and is the founder of the ARTIS Ventures’ Healthcare Pioneers, which brings together some of the world’s brightest minds to accelerate and incubate life-changing ideas in healthcare.

Prior to ARTIS, he co-founded and served as the general manager of the GLG Institute –the world’s largest network of CEOs and CXOs. Here, he worked with C-suite executives from Pfizer, AstraZeneca, Teva, McDonald’s, and others to build a forum to connect retired executives with aspiring leaders. He previously served as a consultant at McKinsey & Company.

Bailey received his PhD in Biomedical Engineering from the Johns Hopkins School of Medicine where he was recognized as both a Siebel and a Medtronic Scholar and member of Sigma Xi. He graduated magna cum laude and phi beta kappa from UC Irvine with a degree in biomedical engineering, and was both a Regents Scholar, Hodson Foundation fellow, Whitaker Foundation Fellow, and Henri Samueli Endowed Scholar.

He has published over 30+ scientific papers/abstracts and holds four provisional patents from his research in nanotechnology for the early detection of cancer. He later broadened the technology for advancing personalized chemotherapy. He has been recognized as one of the world’s leading biomedical engineers by the Siebel Foundation.

Bailey is a seasoned speaker, having presented on the topic of biotech, healthcare, and entrepreneurism at events including DTx West, Health 2.0, GIANT Health, Johns Hopkins Research Symposium on Engineering in Healthcare, AWIS Summit, and East/West CEO, and has been a distinguished guest lecturer at UC Irvine and Johns Hopkins. He has been quoted as an expert on biotech and healthcare in CNBC, Venture Capital Journal, Wall Street Journal, and more.

Vasudev was named to SF Business Times’ 40 Under 40 for his dedication to TechBio as an investor with a STEM background in 2021